Share this article
Share this article
TORONTO, Jan. 21, 2021 /CNW/ - Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The Phase 3 BLAZE-2 COVID-19 prevention trial – conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), and the COVID-19 Prevention Network (CoVPN) – enrolled residents and staff at skilled nursing and assisted living facilities, commonly referred to as nursing homes, across the U.S.
The 965 participants who tested negative for the SARS-CoV-2 virus at baseline (299 residents and 666 staff) were included in the analysis of primary and key secondary endpoints for assessing bamlanivimab as a preventative, while the 132 participants (41 residents and 91 staff) who tested positive for the virus at baseline were included in ex
A study of nursing home residents found the monoclonal antibody treatment bamlanivimab cut the risk of COVID-19 by up to 80%, maker Eli Lilly announced.
email article
Bamlanivimab, the monoclonal antibody authorized to treat less-severe cases of COVID-19, reduced the risk of contracting symptomatic disease among nursing home residents and staff in the placebo-controlled BLAZE-2 trial, said manufacturer Eli Lilly on Thursday.
After 8 weeks of follow-up, incidence of symptomatic COVID-19 was significantly lower among all individuals receiving the drug compared with placebo (OR 0.43).
And a pre-specified group of nursing home residents had even lower odds of symptomatic disease than those in the control group (OR 0.20), the company said.
These results of the phase III BLAZE-2 trial were announced via press release. The trial was conducted in partnership with the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, and the COVID-19 Prevention Network. Lilly promised to submit the data for peer-reviewed publication and presentation at a future medical meeting.
A study of nursing home residents found the monoclonal antibody treatment bamlanivimab cut the risk of COVID-19 by up to 80%, maker Eli Lilly announced.